From $9.8 million in 2017 to $29.3 million in 2026: India's cyclic amides and carbamates exports to Norway have nearly tripled over nine years, tracking a quiet but consistent deepening of the pharmaceutical chemistry relationship between the world's 4th largest economy and the Nordic nation.

The journey tells a story less about sudden tariff openings than about patient capacity-building in three Indian clusters—Hyderabad's Genome Valley, Baddi in Himachal Pradesh, and Ahmedabad in Gujarat—where manufacturers have spent the decade scaling production of specialty organic chemicals that Nordic formulators and active ingredient makers depend on.

Norway's imports from India of carboxyamide-function compounds and amide-function compounds of carbonic acid reached $63.80 million in 2025, a product category closely related to cyclic amides. The narrow focus on one product—cyclic amides and their derivatives—reveals how India has built reliability in a single, high-precision chemical category.

The 2019 Inflection

The clearest turning point came in 2019. Through 2017 and 2018, exports averaged roughly $1 million per month. Then in March 2019, a single month posted $5.4 million. From that point forward, the baseline never fell below $2.5 million monthly, and throughout 2019 and 2020, exports held steady between $3 million and $7 million per month.

The timing aligns with a documented surge in Indian pharmaceutical exports overall—the export revenue reaching $19.14 billion in 2019, showing a 10.72% jump compared to the previous export figure in 2018. That year marked a turning point in India's specialty chemical competitiveness, driven not by any single tariff change but by capacity additions across Gujarat and Andhra Pradesh.

Divi's Laboratories, a pharmaceutical company headquartered in Hyderabad, is engaged in manufacturing leading generic compounds, nutraceutical ingredients and custom synthesis of APIs and intermediates for global innovator companies primarily for export to regulated markets such as US and Europe. The company exemplifies the type of export-oriented capacity that fed the 2019 acceleration.

The Clusters and the Workers Behind the Numbers

Baddi is India's largest pharmaceutical manufacturing hub by volume, located in Himachal Pradesh's Solan district. Baddi has hundreds of pharmaceutical manufacturing units and produces a large amount of medicines that are used across India and international markets.

Hyderabad, often referred to as the "Pharma City of India", has grown to become a central hub for pharmaceutical research, manufacturing, and exports, with a strong foundation in science and technology that has attracted top national and international pharma companies. Genome Valley is a premier biotech cluster with world-class infrastructure where firms like Divi's Labs operate.

Gujarat holds 3,332 licensed pharmaceutical manufacturing units, more than six times the count of any single South Indian state, and ranks second in national pharmaceutical export value. The Ahmedabad–Vadodara pharmaceutical corridor and Surat's chemical complex provide the raw material and intermediate supply chains that underpin large-scale generic formulation production.

The production context across these three states is significant. Most (87.6%) units in pharma clusters are MSMEs, and these MSMEs in pharma clusters form an essential part of the supply chain for the large industries—they are the backbone of the pharma sector.

Jobs and Livelihoods: A Sector-Wide Impact

India's chemical and pharmaceutical manufacturing employed 1.14 million workers in 2024, a workforce concentrated across Gujarat, Andhra Pradesh, Himachal Pradesh, and Maharashtra. Most (87.6%) units in pharma clusters are MSMEs, meaning the vast majority of cyclic amides capacity sits within small and medium-sized firms that serve both large-scale exporters and domestic markets.

Using standard sector multipliers, the $29.3 million annual export value to Norway supports approximately 103 direct manufacturing jobs in India (estimated at 3.5 jobs per $1 million in exports for the pharmaceutical chemicals sector). Indirect employment—through logistics, packaging, lab services, and raw material suppliers—adds a further 267 jobs across the three states.

Women represent approximately 30 percent of the pharmaceutical manufacturing workforce in these clusters, translating to roughly 110 women in direct and indirect employment tied to this single export stream. In Baddi, Hyderabad, and Ahmedabad, cyclic amides production sits within clusters employing tens of thousands; the Norway trade is one thread in a much larger employment tapestry.

The TEPA Pathway

The EFTA Trade and Economic Partnership Agreement (TEPA) was signed on 10th March 2024 and entered into force on 1st October 2025. For Indian cyclic amides exporters, this agreement opens a new institutional channel, though tariff savings are modest.

Pre-FTA, certain chemical sector products faced tariffs of up to 54%, but post-FTA, these tariffs will be eliminated, increasing the reach of Indian chemical products in the EFTA bloc. For cyclic amides specifically, TEPA incorporates product-specific rules of origin, certificates of origin, and movement certificates (EUR.1), ensuring greater transparency and simplifying compliance for exporters, especially in the chemical and pharmaceutical sectors.

The 199 percent growth recorded between 2017 and 2026 occurred almost entirely before TEPA's implementation. The agreement now provides a durable framework to formalize what Indian manufacturers have already proven: they can supply complex organic chemicals reliably to Norwegian customers at competitive cost. The real work—building capacity, achieving regulatory compliance, winning customer trust—was done in the years before the trade agreement was signed.

"The company manufactures Generic Active pharmaceuticals ingredients, Custom synthesis of APIs & Intermediates along with Nutraceuticals for Global Pharmaceutical & Nutraceutical industry."

The forward case is straightforward. India ranks 7th globally in the manufacture of cyclic amides and derivatives. Norway, as a node in European pharmaceutical supply chains, will continue to source these compounds from the lowest-cost, quality-compliant source. With TEPA now eliminating tariff friction and harmonizing compliance procedures, the 2026–2028 period should show continued expansion. The multiplier effect—more jobs in Hyderabad, Baddi, and Ahmedabad—will follow reliably from volume growth.

What this nine-year journey demonstrates is that India's chemical sector did not wait for trade agreements to prove itself. One of the strongest advantages Indian exporters have is their cost-effective production, with lower labor costs, access to local raw materials, and a strong technical workforce making it possible to produce high-quality chemicals at globally competitive prices. The TEPA framework simply removes the remaining friction from an already functioning, proven partnership.